Priority Voucher Leads to Rapid Approval of Teclistamab in Myeloma

The recent FDA approval of teclistamab (Tecvayli) in combination with daratumumab (Darzelex) represents a significant shift in the treatment of relapsed/refractory multiple myeloma (R/R MM). According to Luciano Costa, MD, PhD, Director of the Multiple Myeloma Research and Treatment Program at the University of Alabama at Birmingham, this regulatory milestone is grounded in the robust data from the MajesTEC-3 trial (NCT05083169).

Trial Design and Patient Population

MajesTEC-3 was a large-scale, global clinical trial involving 600 patients. The study specifically enrolled patients who had received at least one prior line of therapy and had been exposed to both proteasome inhibitors (PIs) and lenalidomide. Eligible participants had not previously been exposed to BCMA-directed therapy and their disease was not refractory to the anticipated monoclonal antibody.

Participants were randomly assigned to receive the combination of teclistamab and daratumumab or standard daratumumab-based triplets, such as Dara-Pd (daratumumab, pomalidomide, and dexamethasone) or Dara-Vd (daratumumab, bortezomib, and dexamethasone).

Efficacy and Clinical Impact

Data from the first interim analysis, presented at the 2025 American Society of Hematology Annual Meeting and published in the New England Journal of Medicine, demonstrated a “tremendous improvement” in patient outcomes. With a median follow-up of just over 34 months, the experimental arm achieved a progression-free survival hazard ratio of 0.17. This clinical benefit extended to overall survival, which showed a hazard ratio of 0.46.

Costa noted that the strength of these findings led the FDA to issue a national priority voucher, which accelerated the data appraisal process. This allowed the transition from the first public disclosure of data to full treatment approval to occur within just 3 months. Costa emphasized that this regimen is now a preferred option for this patient profile, offering unprecedented disease control that was previously only seen in later lines of therapy.